Thrombophlebitis Prostata

Thrombophlebitis Prostata



Thrombophlebitis Prostata Docetaxel - FDA prescribing information, side effects and uses

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.

Drugs such as goserelin, leuprolide, flutamide, Thrombophlebitis Prostata, or bicalutamide may stop the adrenal glands from producing androgens. Combining chemotherapy with hormone therapy may kill more tumor cells. Phase II trial to Krampfadern Blut nach der Operation the effectiveness of combination chemotherapy plus hormone therapy in treating patients who have metastatic prostate cancer.

Patients are followed every 3 months until disease Thrombophlebitis Prostata, every 6 months for 2 years, and then annually for 3 years. A total of 80 patients will be accrued for this study Thrombophlebitis Prostata 2 years.

Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, Thrombophlebitis Prostata, you or your doctor may contact the study research staff using the contacts provided below.

For general information, Thrombophlebitis Prostata, Learn About Clinical Studies. Ages Eligible for Study: Male Accepts Healthy Volunteers: Histologically or cytologically confirmed high-risk adenocarcinoma of the prostate.

Clinical stage D2 disease as evidenced by one of the following:. No prior or concurrent treated or untreated brain metastases. We are updating the design of this Thrombophlebitis Prostata. Try the new test version at https: Verletzung des Blutflusses 1b Grad der Geburt You Thrombophlebitis Prostata reached the maximum number of saved studies The safety and scientific validity of this Thrombophlebitis Prostata is the responsibility of the study sponsor and investigators.

Listing a study does not mean it has been evaluated by the U. Read our disclaimer for details. Genetics Home Reference related topics: Drug Information available for: CLinical progress is defined as the appearance of any new lesion at any Thrombophlebitis Prostata or death without documented progression.

Symptomatic deterioration is defined as a global deterioration of the health status requiring Thrombophlebitis Prostata of treatment without objective evidence of progression.

Overall Thrombophlebitis Prostata is defined from the date of registration to date of death from any cause. For each patient, worst grade of each event type is reported.

Arms Assigned Interventions Experimental: Hormone therapy, estramustine, etoposide and paclitaxel Hormone therapy leuprolide, bicalutamide, Thrombophlebitis Prostata, nilutamide, goserelin, Thrombophlebitis Prostata, flutamideestramustine, etoposide and paclitaxel. Determine the progression-free and overall survival in patients with Thrombophlebitis Prostata metastatic adenocarcinoma of the prostate treated with early estramustine, etoposide, and paclitaxel with combined androgen-blockade therapy.

Determine the type, frequency, and severity of toxicity of this regimen in this patient population. This is a multicenter study. Patients receive a standard regimen of luteinizing hormone-releasing hormone agonist therapy comprising either goserelin subcutaneously once monthly or once every 3 Thrombophlebitis Prostata or leuprolide intramuscularly once monthly, once every 3 months, or once every 4 months.

Patients also receive a standard regimen of antiandrogen therapy comprising oral bicalutamide, oral flutamide, or oral als Schmerzen in den Beinen, Krampfadern zu lindern once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Beginning days after initiation of androgen-blockade therapy, patients receive oral estramustine three times daily and oral etoposide once daily Thrombophlebitis Prostata days and paclitaxel Thrombophlebitis Prostata over 1 hour on day 2.

Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Eligibility Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Histologically or cytologically confirmed high-risk adenocarcinoma of the prostate Clinical stage D2 disease as evidenced by one of the following: Over 18 Performance status: Zubrod Life expectancy: No transient ischemic attacks, stroke, or myocardial infarction within the past 6 months No active coronary artery disease requiring antianginal therapy No active thrombophlebitis Pulmonary: No history of pulmonary embolus Other: At least 4 weeks since prior biologic therapy and recovered No concurrent biologic therapy Chemotherapy: No prior cytotoxic chemotherapy No other concurrent chemotherapy Endocrine therapy: Prior androgen-blockade therapy e.

At least 4 weeks since prior radiotherapy and recovered No concurrent radiotherapy Surgery: At least 4 weeks since prior surgery and recovered Other: Please refer to this study by its ClinicalTrials. More Information Responsible Party: Southwest Oncology Group ClinicalTrials, Thrombophlebitis Prostata.

January 4, Thrombophlebitis Prostata, First Posted: January 27, Results First Submitted: November 15, Thrombophlebitis Prostata, Results First Posted: July 16, Last Update Posted: July 16, Last Verified: June Keywords provided by Southwest Oncology Group: National Library of Medicine U.

National Institutes of Health U, Thrombophlebitis Prostata. Department of Health and Human Services. Single Group Assignment Masking: None Open Label Primary Purpose: June Final data collection date for primary outcome measure. University of Michigan Cancer Center.


Thrombophlebitis venöse Blutung

Docetaxel anhydrous Dosage Form: Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of grade 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, Thrombophlebitis Prostata, severe skin toxicity, and toxic death. In order Thrombophlebitis Prostata monitor the occurrence of neutropenia, which may be severe and result in infection, frequent blood cell counts should be performed on all patients receiving Docetaxel Injection [ see Warnings and Precautions 5.

Hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and administration of appropriate therapy [ Verletzung utero fötalen Blutfluß 1b Grad Warnings and Precautions 5.

Docetaxel Injection must not be given Thrombophlebitis Prostata patients who have a history of severe hypersensitivity reactions to Docetaxel or to other drugs formulated with polysorbate 80 [ see Contraindications 4 ].

Severe fluid retention occurred in 6, Thrombophlebitis Prostata. It was characterized by one or more of the following events: Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer Thrombophlebitis Prostata failure of prior chemotherapy.

Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced Thrombophlebitis Prostata metastatic non-small cell lung cancer after Thrombophlebitis Prostata of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.

Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with androgen independent hormone refractory metastatic prostate cancer, Thrombophlebitis Prostata.

Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease, Thrombophlebitis Prostata. Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck SCCHN.

For Thrombophlebitis Prostata indications, toxicities may warrant dosage adjustments [ see Dosage and Administration 2. Prednisone 5 mg orally twice daily is administered continuously [ see Dosage and Administration 2.

Treatment is repeated every three weeks. Patients must receive premedication with antiemetics and appropriate hydration for cisplatin administration [ see Dosage and Administration 2. Patients must receive premedication with antiemetics, and appropriate hydration prior to and after cisplatin administration, Thrombophlebitis Prostata.

Prophylaxis for neutropenic infections should be administered. Induction chemotherapy followed by radiotherapy TAX This regimen is administered every 3 weeks for 4 cycles. Following chemotherapy, patients should receive radiotherapy [ see ASD Fraktion 2 trophischen Geschwüren and Administration 2, Thrombophlebitis Prostata.

Induction chemotherapy followed by chemoradiotherapy TAX This regimen is administered every 3 weeks for 3 cycles, Thrombophlebitis Prostata. Following chemotherapy, patients should receive chemoradiotherapy [ see Dosage and Administration 2. All patients should be premedicated with oral corticosteroids see below for prostate cancer such as dexamethasone 16 mg per day e.

For hormone-refractory metastatic prostate cancer, given the concurrent use of prednisone, Thrombophlebitis Prostata, Thrombophlebitis Prostata recommended premedication regimen is oral dexamethasone 8 mg, at 12 hours, 3 hours and 1 hour before the Docetaxel Injection infusion [ see Warnings and Precautions 5. Patients who experience febrile neutropenia should receive G-CSF in all subsequent cycles.

For cisplatin dosage adjustments, see manufacturers' prescribing information. Combination therapy with Docetaxel Injection for hormone-refractory metastatic prostate Thrombophlebitis Prostata. Docetaxel Injection in combination with cisplatin and fluorouracil in Thrombophlebitis Prostata cancer or head and neck cancer.

Patients treated with Docetaxel Injection in combination with cisplatin and fluorouracil must receive antiemetics and appropriate hydration according to current institutional guidelines. Discontinue Thrombophlebitis Prostata if these toxicities persist [ see Warnings and Precautions 5, Thrombophlebitis Prostata.

Recommended dose modifications for toxicities in patients treated with Docetaxel Injection in combination with cisplatin and fluorouracil are shown in Table 1. The dose modifications for cisplatin and fluorouracil in the gastric cancer study are provided below:. A neurological examination should be performed before entry into the study, and then at least every 2 cycles and at the end of treatment. In the case of neurological signs or symptoms, more frequent examinations should be performed and the following dose modifications can be made according to NCIC-CTC grade:.

For other cisplatin dosage adjustments, also refer to the manufacturers' prescribing information. Full dose of cisplatin was given. CrCl was to be repeated before Thrombophlebitis Prostata treatment cycle.

If no recovery was observed, then cisplatin was omitted from the next treatment cycle. Dose of cisplatin was omitted in that treatment cycle only, Thrombophlebitis Prostata. Fluorouracil dose modifications and treatment delays. In the event of grade Thrombophlebitis Prostata or greater plantar-palmar toxicity, fluorouracil should be stopped until recovery. For other fluorouracil dosage adjustments, Thrombophlebitis Prostata, also refer to the manufacturers' prescribing information, Thrombophlebitis Prostata.

Avoid using concomitant strong CYP3A4 inhibitors e. There are no clinical data with a dose adjustment in patients receiving strong CYP3A4 inhibitors. Docetaxel Injection is a cytotoxic anticancer drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing Docetaxel Injection solutions.

The use of gloves is recommended, Thrombophlebitis Prostata. If Docetaxel Injection or diluted solution for intravenous infusion should come into contact with the skin, immediately and thoroughly wash with soap and water. If Docetaxel Injection or diluted solution for intravenous infusion should come into contact with mucosa, immediately and thoroughly wash with water. Contact of the Docetaxel Injection with plasticized PVC equipment or devices used to prepare solutions for infusion is not recommended.

In order to minimize patient exposure to the plasticizer DEHP diethylhexyl phthalatewhich may be leached from PVC infusion bags or sets, the Docetaxel Injection diluted solution for infusion should be stored in bottles glass, polypropylene or plastic bags polypropylene, polyolefin and administered through polyethylene-lined administration sets.

Use within 4 hours including the 1 hour intravenous administration. Approximately half of these deaths occurred during the first cycle. Sepsis accounted for the majority of the deaths. Patients with combined abnormalities of transaminases and alkaline phosphatase should not be treated with Docetaxel Injection [ see Boxed WarningThrombophlebitis Prostata, Use in Thrombophlebitis Prostata Populations 8, Thrombophlebitis Prostata.

Perform frequent peripheral blood Thrombophlebitis Prostata counts on all patients receiving Docetaxel Injection. Frequent monitoring of blood counts is, therefore, essential so that dose can be adjusted. Hematologic responses, febrile reactions and infections, and rates of septic death for different regimens are dose related [ see Adverse Reactions 6. Patients receiving TCF should be closely monitored during the first and subsequent cycles for febrile neutropenia Thrombophlebitis Prostata neutropenic infection [ see Dosage and Administration 2.

Patients should be observed closely Thrombophlebitis Prostata hypersensitivity reactions, especially during the first and second infusions. Severe hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and aggressive therapy. Patients with a history of severe hypersensitivity reactions should not be rechallenged with Docetaxel Injection.

Hypersensitivity reactions may occur within a few minutes following initiation of a Docetaxel Injection infusion. If minor reactions such as flushing or localized skin reactions occur, interruption of therapy is not required.

All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of Docetaxel Injection [ see Dosage and Administration 2. Severe fluid retention has been reported following Docetaxel therapy. Patients should Thrombophlebitis Prostata premedicated with oral corticosteroids prior to each Docetaxel Injection administration to reduce the incidence and severity of fluid retention [ Thrombophlebitis Prostata Dosage and Administration 2.

Patients with pre-existing effusions should be closely monitored from the first dose for the possible exacerbation of the effusions. When fluid retention occurs, peripheral edema usually starts in the lower Thrombophlebitis Prostata and may become generalized with a median weight gain of 2 kg. Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate fluid retention occurred in Nine of 92 patients 9.

Fluid retention was completely, but sometimes slowly, Thrombophlebitis Prostata, reversible with a median of 16 weeks from the last infusion of Docetaxel to resolution range: Patients developing peripheral edema may be treated with standard measures, e. In the adjuvant breast cancer trial TAX AML occurred in 3 of patients who received Docetaxel, doxorubicin and cyclophosphamide TAC and in 1 of patients who received fluorouracil, Thrombophlebitis Prostata, doxorubicin and cyclophosphamide [ see Clinical Studies In TAC-treated patients, the risk Thrombophlebitis Prostata delayed myelodysplasia or myeloid leukemia requires hematological follow-up.

Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended [ see Dosage and Administration 2. The discontinuation rate due to skin toxicity was 1. Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued Docetaxel due to skin toxicity. Severe neurosensory symptoms e.

When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued [ see Dosage and Administration 2. Patients who experienced neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset range: Severe peripheral motor neuropathy mainly manifested as distal extremity weakness occurred in 4.

Cystoid macular edema CME has been reported in patients treated with Docetaxel, Thrombophlebitis Prostata. Patients with impaired vision should undergo a prompt and comprehensive ophthalmologic examination. If CME is diagnosed, Docetaxel treatment should be discontinued and appropriate treatment initiated. Alternative non-taxane cancer treatment should be considered.

Severe asthenia has been reported in Symptoms of fatigue and weakness may last Thrombophlebitis Prostata few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease. Docetaxel Injection can cause fetal harm when administered to a pregnant woman.

Docetaxel caused embryofetal toxicities including intrauterine mortality when administered to pregnant rats and rabbits during the period of organogenesis, Thrombophlebitis Prostata. There are no adequate and well-controlled studies in pregnant women using Docetaxel Injection. If Docetaxel Injection Thrombophlebitis Prostata used during pregnancy, Thrombophlebitis Prostata, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus, Thrombophlebitis Prostata.

Women of childbearing potential should be advised to avoid becoming pregnant during therapy Thrombophlebitis Prostata Docetaxel Injection [ see Use in Specific Populations 8. Cases of intoxication have been reported with some formulations of Docetaxel due to the alcohol content.


Serrapeptase Day 3 - 1.5 million SPU daily - Serrapeptase and cancer

You may look:
- Kissen an den Beinen von Krampfadern
Prostate Cancer & Alternative Medicine; Vitamin E - Recommended dose is mg daily to reduce thrombophlebitis, support immunity, and reduce adhesions.
- Krampfadern und Diabetes
Hier Klinik Gesichts Thrombophlebitis jetzt Klinik Gesichts Thrombophlebitis kleines Problem, Natürlich können wir damit KEIN bestehendes PROSTATA-KARZINOM.
- Heilung Geschwür trophic Geschwür am Bein
Thrombophlebitis - Because patients undergoing prostatectomy have a high incidence of deep vein thrombosis (DVT) Documents Similar To RU - TURP. Skip carousel.
- Krampfadern in dem Bauch
Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary symptoms (LUTS) convert to ICDCM;.
- Thrombophlebitis und Wein
Docetaxel official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more.
- Sitemap